10-K: Agenus Inc. Reports 2024 Results, Prioritizes Botensilimab Development

Sentiment:

Annual Results 17 March 2025 4:16 PM

Agenus Inc. outlines its 2024 financial results and strategic realignment, focusing on the development and commercialization of its botensilimab/balstilimab program.

Delay expectedThe company is temporarily postponing preclinical and clinical programs not related to BOT/BAL to focus resources.The company is seeking partnerships, licensing, or joint ventures to fund registration-enabling trials in MSS CRC, which could delay the launch of these trials.

Capital raiseThe company is exploring additional funding through equity offerings, debt financings, collaborations, and asset sales to support operations on an ongoing basis.

Worse than expectedThe company reported significant net losses and has limited cash resources, raising concerns about its ability to continue as a going concern.The company terminated collaborations with BMS, Incyte and Gilead.

Summary

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology therapies.
The company's pipeline includes immune-modulatory antibodies, adoptive cell therapies, and vaccine adjuvants.
Agenus is prioritizing the development of botensilimab (BOT) in combination with balstilimab (BAL), particularly for colorectal cancer (CRC).
In a Phase 2 trial, the BOT75mg + BAL regimen demonstrated a 19% ORR and a 55% disease control rate (DCR) in heavily pretreated MSS mCRC NLM patients.
The company is seeking partnerships, licensing, or joint ventures to fund registration-enabling trials in MSS CRC.
Agenus is temporarily postponing preclinical and clinical programs not related to BOT/BAL to focus resources.
The company reported net losses of $232.3 million for 2024.
As of December 31, 2024, Agenus had $40.4 million in cash and cash equivalents.
The company believes its cash resources will be sufficient to satisfy critical liquidity requirements through the second quarter of 2025.
Agenus is exploring additional funding through equity offerings, debt financings, collaborations, and asset sales.
The company is involved in a securities class action lawsuit and is cooperating with an SEC investigation.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical data for botensilimab and strategic realignments, the significant net losses, limited cash resources, and terminated collaborations create a negative outlook.

Positives

Botensilimab/balstilimab combination shows promising efficacy in heavily pretreated MSS mCRC NLM patients.
Fast Track designation from the FDA for botensilimab/balstilimab in MSS mCRC NLM.
Strategic realignment to prioritize botensilimab/balstilimab program.
Advancements in SaponiQx's cGMP STIMULON cultured plant cell (cpc) QS-21 adjuvant.
MiNK Therapeutics' agenT-797 is in a Phase 2 clinical trial for gastric cancer.
Strategic collaboration between SaponiQx, Probius, and Ginkgo Bioworks to develop next-generation vaccine adjuvants.

Negatives

Significant net losses of $232.3 million for 2024.
Limited cash resources, with funding sufficient only through the second quarter of 2025.
Dependence on securing additional funding through various means.
Termination of collaborations with BMS, Incyte and Gilead.
Ongoing securities class action lawsuit and SEC investigation.
FDA advised against pursuing accelerated approval based on current data for BOT/BAL in r/r MSS CRC with NLM.

Risks

Failure to obtain additional financing could hinder development and commercialization efforts.
Clinical trials may reveal adverse events or lack of therapeutic efficacy.
Competition from companies with greater resources and more advanced products.
Regulatory approval process is lengthy and uncertain.
Product candidates may not achieve market acceptance or favorable reimbursement.
Reliance on third parties for manufacturing and clinical trials.
Potential for intellectual property disputes and challenges.
Cybersecurity breaches could disrupt business operations.
Economic downturns and geopolitical instability could negatively impact the company's financial condition.

Future Outlook

Agenus believes its cash resources will be sufficient to satisfy critical liquidity requirements through the second quarter of 2025 and is exploring additional funding through equity offerings, debt financings, collaborations, and asset sales to support operations on an ongoing basis.

Management Comments

Management is diligently addressing the Company's liquidity needs and has continued to adjust spending in order to preserve liquidity.

Industry Context

The immuno-oncology drug landscape is crowded with several competitors developing assets against a number of targets, ranging from small cap to large cap companies, with assets in pre-clinical or clinical stages of development.

Comparison to Industry Standards

The document mentions several competitors with antibody-based products on the market or in clinical development that are directed to the same biological targets as Agenus' programs, including BMS, Merck, Regeneron, Roche/Genentech, AstraZeneca, Merck KGaA, GSK, Coherus Biosciences, Incyte, and Beigene Ltd.
The document also mentions companies developing next-generation anti-CTLA-4 assets, which may be competitive to Agenus' next-generation AGEN1181, including Adagene, BioAtla, Harbour BioMed, OncoC4/BioNTech and Xilio Therapeutics.
The document also mentions companies advancing preclinical or clinical stage CTLA-4 targeting bispecific antibodies or oncolytic viruses as a next-generation approach including Biocad, Jiangsu Alphamab, Macrogenics, Replimune, Sichuan Baili Pharmaceuticals and Xencor.

Legal Proceedings

Agenus is involved in a securities class action lawsuit alleging false and misleading statements related to the efficacy and commercial prospects of botensilimab and balstilimab.
Agenus is cooperating with an SEC investigation seeking records relating to certain of its product candidates, correspondence with the FDA, public disclosure, and other matters.

Related Party Transactions

Agenus performed research and development manufacturing services for Protagenic Therapeutics, Inc., where Dr. Garo H. Armen is Executive Chairman.
Agenus contracted with Avillion Life Sciences LTD for clinical consulting services, where Allison Jeynes, a former member of Agenus' Board of Directors, is chief executive officer.
Agenus used the law firm of Wolf, Greenfield & Sachs, P.C. (Wolf Greenfield), where Dr. Jennifer Buell's spouse is a partner.

Stakeholder Impact

Shareholders face potential dilution from future equity offerings.
Employees may be affected by the strategic realignment and potential workforce reductions.
Patients may benefit from the development of new cancer therapies.
Suppliers and creditors may be impacted by the company's financial condition.

Next Steps

Launch registration-enabling trials in MSS CRC upon completion of strategic transactions.
Continue clinical development of botensilimab/balstilimab combination.
Explore partnerships, licensing, or joint ventures to fund clinical trials.
Seek regulatory approval for botensilimab/balstilimab combination.

Key Dates

Date	Description
2006	Agenus entered into a license agreement and a supply agreement with GSK for QS-21 STIMULON.
January 2015	Agenus began a broad collaboration with Incyte to pursue the discovery and development of antibodies.
February 20, 2015	Agenus issued subordinated promissory notes in the aggregate principal amount of $14.0 million.
January 2018	Agenus sold 100% of all royalties it was entitled to receive from GSK to Healthcare Royalty Partners III, L.P.
December 2018	Agenus entered into a partnership with Gilead relating to five of its antibody programs.
January 2019	The Bill & Melinda Gates Foundation awarded Agenus a grant to develop the plant cell culture process for cpcQS-21 STIMULON.
June 2020	Agenus entered into a license and collaboration agreement with Betta Pharmaceuticals to collaborate on the development and commercialization of balstilimab and zalifrelimab in greater China.
May 2021	Agenus entered into a license agreement with BMS relating to its anti-TIGIT bispecific antibody program.
October 2021	Agenus completed the initial public offering (IPO) of MiNK Therapeutics.
April 2023	BOT in combination with BAL received Fast Track designation from the FDA for the treatment of patients with non-MSI-H and/or dMMR metastatic colorectal cancer without active liver involvement.
July 2024	BMS notified Agenus that it was voluntarily terminating the BMS License Agreement, effective as of January 26, 2025.
August 2024	Gilead elected not to exercise the option to license AGEN2373, and the option and license agreement was formally terminated.
September 2024	A securities class action lawsuit was filed against Agenus and certain of its executives and directors.
November 26, 2024	Agenus, through a subsidiary, entered into a promissory note for a loan in an aggregate principal amount of $22.0 million.
December 2024	Agenus announced further detail to its strategic realignment to prioritize and focus resources to accelerate the development, registration, and commercialization of its BOT/BAL program.
January 2025	Agenus presented results from the randomized, global Phase 2 trial in refractory MSS mCRC NLM versus standard treatments at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) Annual Meeting in San Francisco.
February 2025	Incyte notified Agenus of their intent to terminate the entire Collaboration Agreement, effective February 2026.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.